Nombre del producto:5-Bromo-6-chloronicotinic acid

IUPAC Name:5-bromo-6-chloropyridine-3-carboxylic acid

CAS:29241-62-1
Fórmula molecular:C6H3BrClNO2
Pureza:95%
Número de catálogo:CM102696
Peso molecular:236.45

Unidad de embalaje Stock disponible Precio($) Cantidad
CM102696-100g in stock ȤȅŪ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :29241-62-1
Fórmula molecular:C6H3BrClNO2
Punto de fusión:-
Código de sonrisas:O=C(O)C1=CN=C(Cl)C(Br)=C1
Densidad:
Número de catálogo:CM102696
Peso molecular:236.45
Punto de ebullición:370°C at 760 mmHg
Nº Mdl:MFCD01927098
Almacenamiento:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Asciminib
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.

Related Products